SLC9A3-AS1 is upregulated in NSCLC, and the SLC9A3-AS1 gene knockout hinders NSCLC progression by targeting miR-760, implying that it may have a role as a new biomarker and therapeutic target of NSCLC (25). This evidence concerns the gene SLC9A3 and non-small cell lung carcinoma.